Table 1.
Characteristics of the study population
| Characteristic | All sarcoma survivors*(N=1094) | Upper Extremity (N=274) | Lower Extremity (N=820) | p-value** | |
|---|---|---|---|---|---|
| Sex | Male | 539 (49.3) | 126 (46.0) | 413 (50.4) | 0.209 |
| Female | 555 (50.7) | 148 (54.0) | 407 (49.6) | ||
|
| |||||
| Race/Ethnicity | White | 957 (87.5) | 244 (89.1) | 713 (87.0) | 0.767 |
| Black | 50 (4.6) | 10 (3.6) | 40 (4.9) | ||
| Hispanic | 49 (4.5) | 13 (4.7) | 36 (4.4) | ||
| Other | 34 (3.1) | 6 (2.2) | 28 (3.4) | ||
| Unknown | 4 (0.4) | 1 (0.4) | 3 (0.4) | ||
|
| |||||
| Age at diagnosis (years) | 0–4 | 97 (8.9) | 37 (13.5) | 60 (7.3) | <.001 |
| 5–9 | 179 (16.4) | 62 (22.6) | 117 (14.3) | ||
| 10–14 | 374 (34.2) | 87 (31.8) | 287 (35.0) | ||
| 15–20 | 444 (40.6) | 88 (32.1) | 356 (43.4) | ||
|
| |||||
| Age at baseline survey (years) | <20 | 101 (9.2) | 35 (12.8) | 66 (8.0) | 0.041 |
| 20–29 | 454 (41.5) | 119 (43.4) | 335 (40.9) | ||
| 30–39 | 497 (45.4) | 113 (41.2) | 384 (46.8) | ||
| 40–49 | 42 (3.8) | 7 (2.6) | 35 (4.3) | ||
|
| |||||
| Survival time at baseline survey (years) | 5–9 | 98 (9.0) | 22 (8.0) | 76 (9.3) | 0.682 |
| 10–14 | 362 (33.1) | 97 (35.4) | 265 (32.3) | ||
| 15–19 | 369 (33.7) | 86 (31.4) | 283 (34.5) | ||
| 20–24 | 231 (21.1) | 62 (22.6) | 169 (20.6) | ||
| 25–29 | 34 (3.1) | 7 (2.6) | 27 (3.3) | ||
|
| |||||
| Age at 2003 questionnaire (years)* | <20 | 4 (0.5) | 3 (1.5) | 1 (0.2) | 0.114 |
| 20–29 | 96 (11.8) | 25 (12.5) | 71 (11.6) | ||
| 30–39 | 420 (51.7) | 108 (54.0) | 312 (50.9) | ||
| 40–49 | 285 (35.1) | 63 (31.5) | 222 (36.2) | ||
| 50+ | 8 (1.0) | 1 (0.5) | 7 (1.1) | ||
|
| |||||
| Survival time at 2003 questionnaire (years)* | 15–19 | 172 (21.2) | 41 (20.5) | 131 (21.4) | 0.566 |
| 20–24 | 288 (35.4) | 64 (32.0) | 224 (36.5) | ||
| 25–29 | 260 (32.0) | 71 (35.5) | 189 (30.8) | ||
| 30–34 | 93 (11.4) | 24 (12.0) | 69 (11.3) | ||
|
| |||||
| Age at 2007 questionnaire (years) * | 20–29 | 25 (3.5) | 12 (6.7) | 13 (2.4) | 0.037 |
| 30–39 | 227 (31.9) | 59 (33.0) | 168 (31.5) | ||
| 40–49 | 397 (55.8) | 96 (53.6) | 301 (56.5) | ||
| 50+ | 63 (8.8) | 12 (6.7) | 51 (9.6) | ||
|
| |||||
| Survival time at 2007 questionnaire (years)* | 20–24 | 164 (23.0) | 42 (23.5) | 122 (22.9) | 0.843 |
| 25–29 | 257 (36.1) | 60 (33.5) | 197 (37.0) | ||
| 30–34 | 223 (31.3) | 60 (33.5) | 163 (30.6) | ||
| 35+ | 68 (9.6) | 17 (9.5) | 51 (9.6) | ||
|
| |||||
| Diagnosis | Ewings sarcoma | 178 (16.3) | 60 (21.9) | 118 (14.4) | <.001 |
| Osteosarcoma | 536 (49.0) | 62 (22.6) | 474 (57.8) | ||
| Soft tissue sarcoma | 350 (32.0) | 141 (51.5) | 209 (25.5) | ||
| Other bone tumors | 30 (2.7) | 11 (4.0) | 19 (2.3) | ||
|
| |||||
| Anthracyclines | None | 362 (35.6) | 125 (48.3) | 237 (31.3) | <.001 |
| Any | 655 (64.4) | 134 (51.7) | 521 (68.7) | ||
|
| |||||
| Alkylating Agents | None | 430 (42.9) | 106 (42.2) | 324 (43.1) | 0.800 |
| Any | 572 (57.1) | 145 (57.8) | 427 (56.9) | ||
|
| |||||
| Platinum | None | 865 (81.1) | 240 (88.6) | 625 (78.6) | <.001 |
| Any | 201 (18.9) | 31 (11.4) | 170 (21.4) | ||
|
| |||||
| Vincristine | None | 444 (40.6) | 105 (38.3) | 339 (41.3) | 0.378 |
| Any | 650 (59.4) | 169 (61.7) | 481 (58.7) | ||
|
| |||||
| Chest Radiation | None | 992 (90.7) | 221 (80.7) | 771 (94.0) | <.001 |
| Any | 102 (9.3) | 53 (19.3) | 49 (6.0) | ||
|
| |||||
| Abdominal Radiation | None | 1081 (98.8) | 269 (98.2) | 812 (99.0) | 0.261 |
| Any | 13 (1.2) | 5 (1.8) | 8 (1.0) | ||
|
| |||||
| Limb Radiation | None | 869 (79.4) | 214 (78.1) | 655 (79.9) | 0.529 |
| Any | 225 (20.6) | 60 (21.9) | 165 (20.1) | ||
|
| |||||
| Thoracotomy | Yes | 135 (12.3) | 21 (7.7) | 114 (13.9) | 0.007 |
| No | 959 (87.7) | 253 (92.3) | 706 (86.1) | ||
|
| |||||
| Limb Surgery | Above Knee Amputation | 381 (34.8) | 3 (1.1) | 378 (46.1) | <.001 |
| Below Knee Amputation | 44 (4.0) | 0 (0.0) | 44 (5.4) | ||
| Arm Amputation | 39 (3.6) | 39 (14.2) | 0 (0.0) | ||
| Limb sparing | 212 (19.4) | 76 (27.7) | 136 (16.6) | ||
| No surgery | 418 (38.2) | 156 (56.9) | 262 (32.0) | ||
*
1094 persons completed the baseline survey, 813 the 2003 questionnaire, and 712 the 2007 questionnaire
**
p-value based on chi-square test